Trial Profile
MULTICENTER PHASE II TRIAL OF TARCEVA COMBINED WITH FIXED DOSE-RATE GEMCITABINE INFUSION AS FIRST LINE TREATMENT OF ADVANCED, UNRESECTABLE PANCREATIC CANCER.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 May 2011
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Gemcitabine (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 31 May 2011 New trial record